Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1967 1
1968 2
1973 1
1974 1
1977 3
1978 1
1979 2
1980 2
1981 3
1982 3
1983 4
1984 2
1985 4
1986 2
1987 5
1988 4
1989 1
1990 3
1991 1
1992 3
1993 4
1994 2
1995 5
1996 4
1997 3
1998 4
1999 2
2000 5
2001 2
2002 5
2003 3
2004 4
2005 4
2006 11
2007 8
2008 10
2009 10
2010 10
2011 15
2012 7
2013 15
2014 20
2015 28
2016 27
2017 27
2018 29
2019 32
2020 36
2021 31
2022 35
2023 35
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

456 results

Results by year

Filters applied: . Clear all
Page 1
HSP47 levels determine the degree of body adiposity.
Shin J, Toyoda S, Okuno Y, Hayashi R, Nishitani S, Onodera T, Sakamoto H, Ito S, Kobayashi S, Nagao H, Kita S, Otsuki M, Fukuhara A, Nagata K, Shimomura I. Shin J, et al. Among authors: toyoda s. Nat Commun. 2023 Nov 11;14(1):7319. doi: 10.1038/s41467-023-43080-x. Nat Commun. 2023. PMID: 37951979 Free PMC article.
Vascular functional tests and preemptive medicine.
Tanaka A, Toyoda S, Node K. Tanaka A, et al. Among authors: toyoda s. Hypertens Res. 2021 Jan;44(1):117-119. doi: 10.1038/s41440-020-00546-5. Epub 2020 Sep 3. Hypertens Res. 2021. PMID: 32884123 Free PMC article. No abstract available.
Pleiotropic effects of calcium channel blockers.
Toyoda S, Sakuma M, Node K, Inoue T. Toyoda S, et al. Hypertens Res. 2018 Apr;41(4):230-233. doi: 10.1038/s41440-018-0014-8. Epub 2018 Feb 15. Hypertens Res. 2018. PMID: 29449704 No abstract available.
Inflammation in pulmonary artery hypertension.
Sakuma M, Toyoda S, Inoue T, Node K. Sakuma M, et al. Among authors: toyoda s. Vascul Pharmacol. 2019 Jul-Aug;118-119:106562. doi: 10.1016/j.vph.2019.05.002. Epub 2019 May 18. Vascul Pharmacol. 2019. PMID: 31112745 Review. No abstract available.
Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial.
Ito S, Takahama H, Asakura M, Abe Y, Ajioka M, Anzai T, Arikawa T, Hayashi T, Higashino Y, Hiramitsu S, Iwahashi N, Izumi C, Kimura K, Kinugawa K, Kioka H, Lim YJ, Matsuoka K, Matsuoka S, Motoki H, Nakamura S, Nakayama T, Nomura A, Sasaoka T, Takiuchi S, Toyoda S, Ueda T, Watanabe T, Yamada A, Yamamoto M, Sozu T, Kitakaze M. Ito S, et al. Among authors: toyoda s. Sci Rep. 2023 Aug 2;13(1):12517. doi: 10.1038/s41598-023-39779-y. Sci Rep. 2023. PMID: 37532820 Free PMC article. Clinical Trial.
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Tanaka A, et al. Among authors: toyoda s. Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y. Cardiovasc Diabetol. 2023. PMID: 37525257 Free PMC article. Clinical Trial.
456 results